Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial

Table 2 Primary and secondary outcomes

	Hydrocortisone (n = 98)	Placebo (n = 99)	Relative risk (95 % CI)	p Value^a
Primary outcome
Mortality at 28 days, n (%)	22 (22.5)	27 (27.3)	0.82 (0.50–1.34)	0.51
Secondary outcomes
Mortality at 60 days, n (%)	34 (34.7)	40 (40.4)	0.86 (0.60–1.23)	0.46
Duration of mechanical ventilation up to day 28, days	11.8 ± 7.8	13.9 ± 9.0		0.17
Mechanical ventilation-free days to day 28	12.0 ± 9.7	9.7 ± 10.0		0.17
Duration of vasopressor treatment,^b days	4.8 ± 3.0	6.8 ± 5.7		0.16
Renal replacement therapy, n (%)	22 (22.4)	22 (22.2)	1.01 (0.86–1.16)	1.00
Duration of renal replacement therapy dependent,^c days	8.1 ± 6.6	8.2 ± 5.2		0.94
Alive on day 28 without organ support, n (%)	64 (65.3)	55 (55.6)	1.18 (0.94–1.48)	0.19
Organ support-free days to day 28^d	11.9 ± 9.7	9.5 ± 9.8		0.13

Unless specified otherwise, data are reported as mean ± SD
^aFor continuous variables, p values were calculated using the Wilcoxon-Mann-Whitney test
^bData calculated for the patients who received vasopressors
^cData calculated for the patients who received renal replacement therapy
^dOrgan support includes the use of mechanical ventilation, vasopressors, or renal replacement therapy

ISSN: 1364-8535